Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
Prnewswire· 2024-08-01 18:45
Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes  INDIANAPOLIS, Aug. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT ph ...
TC Energy declares quarterly dividends
Newsfilter· 2024-08-01 18:35
文章核心观点 - 公司宣布派发2024年第三季度普通股股息,每股0.96美元,以及优先股股息[1][2][3] - 公司股票在多伦多证券交易所和纽约证券交易所上市,股票代码为TRP[7] - 公司是一家拥有7000多名员工的能源问题解决者,致力于安全运输、发电和储存北美所需的能源[6] 公司概况 - 公司是一家能源公司,主要从事天然气管道运输、发电和储能业务[6] - 公司在多伦多证券交易所和纽约证券交易所上市,股票代码为TRP[7] 股息信息 - 公司宣布派发2024年第三季度普通股股息,每股0.96美元,将于2024年10月31日支付给9月27日登记在册的股东[1] - 公司宣布派发2024年第三季度优先股股息,将于9月27日、10月30日和8月30日支付给相关登记在册的股东[2][3] - 公司的股息属于加拿大税法下的合格股息,适用增加的股息税收抵免[4] - 通过公司的股息再投资计划购买的普通股将以100%的加权平均价格在多伦多证券交易所购买[5]
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
Newsfilter· 2024-08-01 18:31
文章核心观点 - 公司在thalassemia和儿童PK缺乏症领域取得重大进展,包括完成ENERGIZE-T和ACTIVATE-KidsT临床试验,并计划在2024年底前向FDA提交thalassemia适应症的补充新药申请[1][2][3][6] - 公司与Royalty Pharma签署了9.05亿美元的收购协议,出售vorasidenib的版权收益权,预计将获得总计11亿美元的付款[2] - 公司PYRUKYND®在第二季度的净收入为860万美元,患者人数持续增加,现金储备充足,为未来发展奠定了基础[4][7][12] 根据目录分别总结 PYRUKYND®收入和患者情况 - PYRUKYND®第二季度净收入860万美元,环比增长5%,主要由于患者需求增加[7] - 完成处方登记的独特患者总数达201人,较第一季度增加7% - 正在接受PYRUKYND®治疗的患者总数为128人,较第一季度增加7%[7] thalassemia临床试验进展 - 完成ENERGIZE-T III期临床试验,达到主要和所有关键次要终点[7] - 在欧洲血液学会2024年会议上,公布了ENERGIZE III期临床试验的阳性结果[7] - 计划在2024年底前向FDA提交thalassemia适应症的补充新药申请[7] 儿童PK缺乏症临床试验进展 - 完成ACTIVATE-KidsT III期临床试验,公布了初步结果,将在未来医学会议上进行更详细分析[7] - 完成ACTIVATE-Kids III期临床试验的患者入组,预计2025年公布初步结果[7] 公司发展动态 - 与Royalty Pharma签署9.05亿美元的收购协议,出售vorasidenib的版权收益权,预计将获得总计11亿美元的付款[2] - 与NewBridge Pharmaceuticals签署分销协议,在海湾合作委员会地区推广PYRUKYND®[7] 未来重点里程碑 - 2024年底前向FDA提交thalassemia适应症的补充新药申请[7] - 2024年底前完成RISE UP III期临床试验的患者入组[7] - 2024年中期开始AG-946 II期临床试验[7] - 预计2024年8月20日vorasidenib获FDA批准[7]
JD.com to Report Second Quarter and Interim 2024 Financial Results on August 15, 2024
Newsfilter· 2024-08-01 18:30
文章核心观点 - JD.com将于2024年8月15日发布2024年第二季度未经审计的财务业绩报告 [1][2] - JD.com将于2024年8月15日召开财报电话会议,讨论2024年第二季度的财务业绩 [2][3] - JD.com是一家领先的供应链技术和服务提供商,致力于为消费者提供随时随地购买所需商品的能力 [5] - JD.com已将其技术和基础设施开放给合作伙伴、品牌和其他行业,作为其零售即服务(Retail as a Service)的一部分,以帮助提高各行业的生产力和创新 [5] 财务数据总结 - JD.com将于2024年8月15日发布2024年第二季度未经审计的财务业绩报告 [1] - JD.com将于2024年8月15日召开财报电话会议,讨论2024年第二季度的财务业绩 [2][3] 公司信息总结 - JD.com是一家领先的供应链技术和服务提供商 [5] - JD.com致力于为消费者提供随时随地购买所需商品的能力 [5] - JD.com已将其技术和基础设施开放给合作伙伴、品牌和其他行业,作为其零售即服务(Retail as a Service)的一部分,以帮助提高各行业的生产力和创新 [5]
Record Results by Willis Lease Finance Corporation with Second Quarter Pre-tax Income of $57.9 million. Willis Declares First, Regular Quarterly Dividend of $0.25 Per Share.
Newsfilter· 2024-08-01 18:30
COCONUT CREEK, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ:WLFC) ("WLFC" or the "Company") today reported record second quarter total revenues of $151.1 million and record quarterly pre-tax income of $57.9 million. The Company also announced its first regular quarterly dividend of $0.25 per share, expected to be paid on August 21, 2024, with a record holder date of August 12, 2024. For the three months ended June 30, 2024, aggregate, core lease rent and maintenance reser ...
Compass Pathways announces second quarter 2024 financial results and business highlights
Newsfilter· 2024-08-01 18:30
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental hea ...
Clearway Energy, Inc. Reports Second Quarter 2024 Financial Results
Newsfilter· 2024-08-01 18:15
Signed agreement with Clearway Group to commit to invest in 314 MW of solar plus storage projectsReceived offer from Clearway Group to invest in a 500 MW solar plus storage projectEntered into new Resource Adequacy contract for Marsh LandingReaffirming 2024 financial guidanceIncreasing the quarterly dividend by 1.7% to $0.4171 per share in the third quarter of 2024, or $1.6684 per share annualizedContinue to target annual dividend per share growth in the upper range of 5% to 8% through 2026 PRINCETON, N.J. ...
Zapp EV Appoints David McIntyre as Chief Operating Officer to Accelerate Global Expansion Strategy
Newsfilter· 2024-08-01 18:05
LONDON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) ("Zapp EV" or the "Company"), owner of "Zapp", the British electric vehicle brand on a mission to revolutionise personal urban mobility, today announced the appointment of David McIntyre as Chief Operating Officer ("COO") effective immediately. David, who previously served as Zapp's Chief Commercial Officer, brings to this newly created role an extensive background in scaling operations for luxury and performance a ...
Sapiens Reports Second Quarter 2024 Financial Results
Prnewswire· 2024-08-01 18:04
ROCHELLE PARK, N.J., Aug. 1, 2024 /PRNewswire/ -- Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the second quarter ended June 30, 2024.Summary Results for Second Quarter 2024 (USD in millions, except per share data) GAAP Non-GAAP Q2 2024 Q2 2023 % Change Q2 2024 Q2 2023 % Change Revenue $136.8 $128.3 6.6 % $136.8 $128.4 6.6 % Gross Profit $60.1 $54.7 10.0 % $62.5 $58.0 7.7  ...
ECARX sells minority stake in HaleyTek to Volvo Cars, will continue to collaborate seamlessly with Volvo Cars and HaleyTek on developing automotive software
Newsfilter· 2024-08-01 18:02
LONDON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. ("ECARX" or "the Company"), a global mobility technology company, announced today that it has sold its minority stake of 40% in HaleyTek AB ("HaleyTek"), a joint venture between Volvo Car Corporation ("Volvo Cars") and ECARX created to develop software for Android-powered infotainment systems, to Volvo Cars. ECARX will continue to collaborate with Volvo Cars and with HaleyTek as a fully-owned subsidiary of Volvo Cars, developing technology soluti ...